Eagle Pharmaceuticals commences review to evaluate range of alternatives

The company has commenced a review process to evaluate a range of potential financing and other alternatives to strengthen its liquidity position and capital structure. There is no deadline or definitive timetable for the completion of this process, and there can be no assurance as to its outcome. The company does not intend to disclose or comment on further developments with respect to this process unless and until it determines that further disclosure is required by law or it otherwise deems appropriate.